NCT06752408View on ClinicalTrials.gov

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

January 16, 2027

Study Completion Date

January 16, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Aumolertinib

Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.

DRUG

Osimertinib

Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.

Trial Locations (1)

100730

Peking Union Medical College Hospital,, Beijing

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

lead

Peking Union Medical College Hospital

OTHER